To develope a novel screening method of histone deacetylase (HDAC) inhibitor having anticancer activity

• Project/Area Number: 25893215
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: Surgical dentistry
• Research Institution: Kyushu Dental College
• Principal Investigator: FUJII SEIKO 九州歯科大学, 歯学部, 助教 (80714659)
• Project Period (FY): 2013-08-30 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000); Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: HDAC阻害剤 / 口腔癌 / テロメラ―ゼ / HDAC / テロメラーゼ / 癌

Outline of Final Research Achievements

Epigenetic modifications such as histone deacetylation are commonly related to tumor development and histone deacetylase (HDAC) inhibitors have been shown to be potential drugs for cancer treatment. Ky-2 is a novel HDAC inhibitor produced by a combination of the HDAC inhibitors TSA and TPX.
In the present study, we investigated the effectiveness of Ky-2 to induce cell cycle and apoptosis in oral squamous carcinoma cells. In addition, we examined the signaling pathway related to the cell cycle and apoptosis in Ky-2-treated oral squamous carcinoma cells.